| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
207,851,000 |
| Market
Cap: |
11.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$31.86 - $59.82 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Catalent is a holding company. Through its subsidiaries, Co. has two operating and reporting segments: Biologics and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells; and vaccines. The Pharma and Consumer Health segment comprises Co.'s capabilities for oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,000 |
1,000 |
| Total Buy Value |
$0 |
$0 |
$49,980 |
$49,980 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
387 |
387 |
11,063 |
116,582 |
| Total Sell Value |
$21,749 |
$21,749 |
$512,581 |
$11,151,362 |
| Total People Sold |
1 |
1 |
12 |
18 |
| Total Sell Transactions |
1 |
1 |
25 |
69 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Grippo Michael J |
SVP, Strategy & Corp. Dev. |
• – – |
2022-07-27 |
4 |
AS |
$107.67 |
$41,776 |
D/D |
(388) |
17,023 |
|
-57% |
|
| Gunther Scott |
SVP, Quality & Reg. Affairs |
• – – |
2022-07-27 |
4 |
AS |
$107.67 |
$42,422 |
D/D |
(394) |
22,350 |
|
-57% |
|
| Hopson Ricky |
Pres, Clinical Dev & Supply |
• – – |
2022-07-27 |
4 |
AS |
$107.67 |
$63,633 |
D/D |
(591) |
17,095 |
|
-57% |
|
| Arnold Jonathan |
SVP & Chief Commercial Ofcr |
• – – |
2022-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,023 |
49,721 |
|
- |
|
| Arnold Jonathan |
SVP & Chief Commercial Ofcr |
• – – |
2022-07-26 |
4 |
S |
$106.90 |
$10,049 |
D/D |
(94) |
48,698 |
|
55% |
|
| Grippo Michael J |
SVP, Strategy & Corp. Dev. |
• – – |
2022-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,301 |
17,411 |
|
- |
|
| Grippo Michael J |
SVP, Strategy & Corp. Dev. |
• – – |
2022-07-26 |
4 |
AS |
$106.90 |
$43,722 |
D/D |
(409) |
16,110 |
|
-55% |
|
| Pravda Ricardo |
SVP & Chief HR Officer |
• – – |
2022-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,301 |
16,638 |
|
- |
|
| Pravda Ricardo |
SVP & Chief HR Officer |
• – – |
2022-07-26 |
4 |
S |
$106.90 |
$45,646 |
D/D |
(427) |
15,337 |
|
55% |
|
| Gunther Scott |
SVP, Quality & Reg. Affairs |
• – – |
2022-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,115 |
22,744 |
|
- |
|
| Gunther Scott |
SVP, Quality & Reg. Affairs |
• – – |
2022-07-26 |
4 |
AS |
$106.90 |
$48,105 |
D/D |
(450) |
21,629 |
|
-55% |
|
| Chiminski John R |
Executive Chair |
• • – |
2022-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
37,165 |
169,547 |
|
- |
|
| Chiminski John R |
Executive Chair |
• • – |
2022-07-26 |
4 |
S |
$106.90 |
$1,035,968 |
D/D |
(9,691) |
132,382 |
|
55% |
|
| Hopson Ricky |
Pres, Clinical Dev & Supply |
• – – |
2022-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
651 |
17,686 |
|
- |
|
| Hopson Ricky |
Pres, Clinical Dev & Supply |
• – – |
2022-07-26 |
4 |
AS |
$106.90 |
$33,353 |
D/D |
(312) |
17,035 |
|
-55% |
|
| Gennadios Aristippos |
Group Pres. Pharma & Consumer |
• – – |
2022-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,859 |
81,643 |
|
- |
|
| Gennadios Aristippos |
Group Pres. Pharma & Consumer |
• – – |
2022-07-26 |
4 |
S |
$106.90 |
$43,081 |
D/D |
(403) |
79,784 |
|
55% |
|
| Carletti Lorenzo |
SVP Global Ops Ph & Cons Hlth |
• – – |
2022-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
837 |
3,786 |
|
- |
|
| Carletti Lorenzo |
SVP Global Ops Ph & Cons Hlth |
• – – |
2022-07-26 |
4 |
S |
$106.90 |
$67,454 |
D/D |
(631) |
2,949 |
|
55% |
|
| Schmidt Kay A |
SVP, Enterprise Functions |
• – – |
2022-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,115 |
14,570 |
|
- |
|
| Schmidt Kay A |
SVP, Enterprise Functions |
• – – |
2022-07-26 |
4 |
S |
$106.90 |
$34,529 |
D/D |
(323) |
13,455 |
|
55% |
|
| Gargiulo Mario |
SVP Global Ops Biologics |
• – – |
2022-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
837 |
4,508 |
|
- |
|
| Gargiulo Mario |
SVP Global Ops Biologics |
• – – |
2022-07-26 |
4 |
S |
$106.90 |
$103,586 |
D/D |
(969) |
3,671 |
|
55% |
|
| Maselli Alessandro |
President & CEO |
• • – |
2022-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
10,221 |
35,304 |
|
- |
|
| Maselli Alessandro |
President & CEO |
• • – |
2022-07-26 |
4 |
S |
$106.90 |
$87,230 |
D/D |
(816) |
25,083 |
|
55% |
|
821 Records found
|
|
Page 8 of 33 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.33 (0.58%) 
